Jorge Plutzky

Jorge Plutzky

Cardiology
70 Francis Street
Carl J. And Ruth Shapiro Cardiovascular Center
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Journal: Circulation
Published: August 18, 2026

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Journal: Circulation. Population health and outcomes
Published: June 22, 2026

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Journal: Endocrine connections
Published: December 19, 2025

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Journal: Endocrine connections
Published: December 04, 2025

Engagement and Weight Change in an Online Weight Management Program in Clinical Settings: An Implementation Project.

Engagement and Weight Change in an Online Weight Management Program in Clinical Settings: An Implementation Project.

Journal: Journal of general internal medicine
Published: November 18, 2025

Flipping the PRDM16 switch in 'multifunctional mesenchymes' may help to define atherosclerotic plaque.

Flipping the PRDM16 switch in 'multifunctional mesenchymes' may help to define atherosclerotic plaque.

Journal: Nature cardiovascular research
Published: November 07, 2025

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Journal: Nature medicine
Published: September 19, 2025

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

Journal: JACC. Advances
Published: September 19, 2025

Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

Journal: American heart journal
Published: August 24, 2025

Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications.

Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications.

Journal: Thrombosis and haemostasis
Published: August 22, 2025

Comparison of PREVENT with the pooled cohort equation for estimating atherosclerotic cardiovascular disease risk among patients with rheumatoid arthritis.

Comparison of PREVENT with the pooled cohort equation for estimating atherosclerotic cardiovascular disease risk among patients with rheumatoid arthritis.

Journal: American journal of preventive cardiology
Published: July 04, 2025

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

Journal: Lancet (London, England)
Published: May 13, 2025
Showing 1-12 of 148

Last Updated: 09/26/2026